Pages that link to "Q73804303"
Jump to navigation
Jump to search
The following pages link to Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group (Q73804303):
Displaying 50 items.
- Fibrates for secondary prevention of cardiovascular disease and stroke (Q24186376) (← links)
- APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study (Q24305221) (← links)
- Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis (Q24541529) (← links)
- Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunities (Q24793111) (← links)
- Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review (Q28220294) (← links)
- Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial (Q28236480) (← links)
- Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients (Q28244205) (← links)
- Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease (Q28287250) (← links)
- Oxidized low-density lipoprotein and peroxisome-proliferator-activated receptor alpha down-regulate platelet-activating-factor receptor expression in human macrophages (Q28348220) (← links)
- Fibrates for primary prevention of cardiovascular disease events. (Q30241199) (← links)
- PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a (Q30476274) (← links)
- All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT. (Q31101617) (← links)
- PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway (Q31793810) (← links)
- A reexamination of the PPAR-alpha activation mode of action as a basis for assessing human cancer risks of environmental contaminants (Q33569334) (← links)
- Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. (Q33576435) (← links)
- Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: clinical aspects (Q33665243) (← links)
- Antiatherosclerotic activity of drugs in relation to nitric oxide function (Q33709262) (← links)
- How to standardize vasomotor tone in serial studies based on quantitation of coronary dimensions? (Q33715543) (← links)
- Screening for cardiovascular disease. Concepts, conflicts, and consensus (Q33786237) (← links)
- Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions (Q33796257) (← links)
- Current, new and future treatments in dyslipidaemia and atherosclerosis (Q33993678) (← links)
- Preventing, stopping, or reversing coronary artery disease--triglyceride-rich lipoproteins and associated lipoprotein and metabolic abnormalities: the need for recognition and treatment (Q34003407) (← links)
- A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis (Q34021096) (← links)
- The role of fibric acid derivatives in the secondary prevention of coronary heart disease (Q34027549) (← links)
- Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis (Q34047291) (← links)
- Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. (Q34068746) (← links)
- New developments in the treatment of low high-density lipoprotein cholesterol (Q34107152) (← links)
- Recent developments in the treatment of hypertriglyceridemia (Q34107158) (← links)
- Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk (Q34107307) (← links)
- Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms (Q34107495) (← links)
- The role of fibric acids in atherosclerosis (Q34109473) (← links)
- Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management (Q34181381) (← links)
- Raising high-density lipoprotein cholesterol and lowering low-density lipoprotein cholesterol as adjunctive therapy to coronary artery revascularization (Q34262634) (← links)
- Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review (Q34262639) (← links)
- Treating mixed dyslipidemias: why and how. (Q34303429) (← links)
- Treating dyslipidaemia in non-insulin-dependent diabetes mellitus -- a special reference to statins (Q34310282) (← links)
- New developments in the prevention of atherosclerosis in patients with low high-density lipoprotein cholesterol (Q34327220) (← links)
- Targeting triglycerides as prognostic indicators and determining lowest values for patient benefit (Q34336868) (← links)
- Use of fibrates and cancer risk: a systematic review and meta-analysis of 17 long-term randomized placebo-controlled trials (Q34428524) (← links)
- Lipid management in the prevention of stroke: a meta-analysis of fibrates for stroke prevention (Q34530349) (← links)
- Orphan nuclear receptors find a home in the arterial wall (Q34586834) (← links)
- Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis. (Q34774354) (← links)
- Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism (Q34808379) (← links)
- Regulation of chemokine expression in atherosclerosis (Q35027759) (← links)
- Impact of statins and beta-blocker therapy on mortality after coronary artery bypass graft surgery (Q35085482) (← links)
- Hepatotoxicity of hypolipidemic drugs (Q35184569) (← links)
- Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment (Q35203793) (← links)
- Lowering triglycerides to modify cardiovascular risk: will icosapent deliver? (Q35230819) (← links)
- Fibrates for treatment of the metabolic syndrome (Q35602779) (← links)
- Association of PPARα Intron 7 Polymorphism with Coronary Artery Disease: A Cross-Sectional Study (Q35684245) (← links)